Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.

Chitlaru T, Israeli M, Rotem S, Elia U, Bar-Haim E, Ehrlich S, Cohen O, Shafferman A.

Vaccine. 2017 Oct 20;35(44):6030-6040. doi: 10.1016/j.vaccine.2017.03.033. Epub 2017 Mar 23.

PMID:
28342664
2.

Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.

Chitlaru T, Israeli M, Bar-Haim E, Elia U, Rotem S, Ehrlich S, Cohen O, Shafferman A.

Sci Rep. 2016 Jan 6;6:18908. doi: 10.1038/srep18908.

3.

Circumventing Y. pestis Virulence by Early Recruitment of Neutrophils to the Lungs during Pneumonic Plague.

Vagima Y, Zauberman A, Levy Y, Gur D, Tidhar A, Aftalion M, Shafferman A, Mamroud E.

PLoS Pathog. 2015 May 14;11(5):e1004893. doi: 10.1371/journal.ppat.1004893. eCollection 2015 May.

4.

High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.

Shafferman A, Birmingham JD, Cron RQ.

Pediatr Rheumatol Online J. 2014 Jul 11;12:26. doi: 10.1186/1546-0096-12-26. eCollection 2014.

5.

Whole-Genome Sequencing of the Nonproteolytic Bacillus anthracis V770-NP1-R Strain Reveals Multiple Mutations in Peptidase Loci.

Cohen-Gihon I, Israeli O, Beth-Din A, Levy H, Cohen O, Shafferman A, Zvi A, Chitlaru T.

Genome Announc. 2014 Feb 13;2(1). pii: e00075-14. doi: 10.1128/genomeA.00075-14.

6.

Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.

Rotem S, Cohen O, Bar-Haim E, Bar-On L, Ehrlich S, Shafferman A.

PLoS One. 2014 Jan 6;9(1):e85215. doi: 10.1371/journal.pone.0085215. eCollection 2014.

7.

YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected].

Zauberman A, Flashner Y, Levy Y, Vagima Y, Tidhar A, Cohen O, Bar-Haim E, Gur D, Aftalion M, Halperin G, Shafferman A, Mamroud E.

PLoS One. 2013 Dec 16;8(12):e83560. doi: 10.1371/journal.pone.0083560. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/0ec1f217-4e7a-4dee-9a71-1076a3ac73f1.

8.

Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.

Shafferman A, Fontaine KR, Cron RQ, Beukelman T.

J Rheumatol. 2014 Jan;41(1):113-8. doi: 10.3899/jrheum.130159. Epub 2013 Dec 1.

PMID:
24293573
9.

Early sensing of Yersinia pestis airway infection by bone marrow cells.

Vagima Y, Levy Y, Gur D, Tidhar A, Aftalion M, Abramovich H, Zahavy E, Zauberman A, Flashner Y, Shafferman A, Mamroud E.

Front Cell Infect Microbiol. 2012 Nov 26;2:143. doi: 10.3389/fcimb.2012.00143. eCollection 2012.

10.

A novel mechanism for antibody-based anthrax toxin neutralization: inhibition of prepore-to-pore conversion.

Mechaly A, Levy H, Epstein E, Rosenfeld R, Marcus H, Ben-Arie E, Shafferman A, Ordentlich A, Mazor O.

J Biol Chem. 2012 Sep 21;287(39):32665-73. Epub 2012 Aug 6.

11.

Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.

Rotem S, Bar-Haim E, Cohen H, Elia U, Ber R, Shafferman A, Cohen O.

Antimicrob Agents Chemother. 2012 Oct;56(10):5406-8. doi: 10.1128/AAC.01104-12. Epub 2012 Jul 30.

12.

A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.

Israely T, Paran N, Lustig S, Erez N, Politi B, Shafferman A, Melamed S.

Virol J. 2012 Jun 18;9:119. doi: 10.1186/1743-422X-9-119.

13.

Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models.

Levy H, Weiss S, Altboum Z, Schlomovitz J, Glinert I, Sittner A, Shafferman A, Kobiler D.

Infect Immun. 2012 Aug;80(8):2623-31. doi: 10.1128/IAI.00244-12. Epub 2012 May 14.

14.

Clusters versus affinity-based approaches in F. tularensis whole genome search of CTL epitopes.

Zvi A, Rotem S, Cohen O, Shafferman A.

PLoS One. 2012;7(5):e36440. doi: 10.1371/journal.pone.0036440. Epub 2012 May 1.

15.

T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.

Levy Y, Flashner Y, Tidhar A, Zauberman A, Aftalion M, Lazar S, Gur D, Shafferman A, Mamroud E.

Vaccine. 2011 Sep 16;29(40):6866-73. doi: 10.1016/j.vaccine.2011.07.059. Epub 2011 Jul 29.

PMID:
21803090
16.

HtrA is a major virulence determinant of Bacillus anthracis.

Chitlaru T, Zaide G, Ehrlich S, Inbar I, Cohen O, Shafferman A.

Mol Microbiol. 2011 Sep;81(6):1542-59. doi: 10.1111/j.1365-2958.2011.07790.x. Epub 2011 Aug 23.

17.

Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response.

Zvi A, Rotem S, Bar-Haim E, Cohen O, Shafferman A.

PLoS One. 2011;6(5):e20050. doi: 10.1371/journal.pone.0020050. Epub 2011 May 20.

18.

Progress and novel strategies in vaccine development and treatment of anthrax.

Chitlaru T, Altboum Z, Reuveny S, Shafferman A.

Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Review.

PMID:
21198675
19.

Identification and characterization of novel and potent transcription promoters of Francisella tularensis.

Zaide G, Grosfeld H, Ehrlich S, Zvi A, Cohen O, Shafferman A.

Appl Environ Microbiol. 2011 Mar;77(5):1608-18. doi: 10.1128/AEM.01862-10. Epub 2010 Dec 30.

20.

The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis.

Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, Shafferman A, Velan B.

PLoS One. 2010 Jun 18;5(6):e11176. doi: 10.1371/journal.pone.0011176.

21.

Next generation OP-bioscavengers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-HuAChE with optimal pharmacokinetics and pseudo-catalytic characteristics.

Kronman C, Cohen O, Mazor O, Ordentlich A, Raveh L, Velan B, Shafferman A.

Chem Biol Interact. 2010 Sep 6;187(1-3):253-8. doi: 10.1016/j.cbi.2009.12.004. Epub 2009 Dec 11.

PMID:
20005217
22.

Proteomic studies of Bacillus anthracis.

Chitlaru T, Shafferman A.

Future Microbiol. 2009 Oct;4(8):983-98. doi: 10.2217/fmb.09.73. Review.

PMID:
19824790
23.

The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague.

Tidhar A, Flashner Y, Cohen S, Levi Y, Zauberman A, Gur D, Aftalion M, Elhanany E, Zvi A, Shafferman A, Mamroud E.

PLoS One. 2009 Sep 14;4(9):e7023. doi: 10.1371/journal.pone.0007023.

24.

Novel and unique diagnostic biomarkers for Bacillus anthracis infection.

Sela-Abramovich S, Chitlaru T, Gat O, Grosfeld H, Cohen O, Shafferman A.

Appl Environ Microbiol. 2009 Oct;75(19):6157-67. doi: 10.1128/AEM.00766-09. Epub 2009 Jul 31.

25.

Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.

Zauberman A, Tidhar A, Levy Y, Bar-Haim E, Halperin G, Flashner Y, Cohen S, Shafferman A, Mamroud E.

PLoS One. 2009 Jun 16;4(6):e5938. doi: 10.1371/journal.pone.0005938.

26.

Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.

Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, Erez N, Orr N, Reuveny S, Ordentlich A, Laub O, Shafferman A, Velan B.

Vaccine. 2009 Mar 10;27(11):1691-9. doi: 10.1016/j.vaccine.2009.01.038. Epub 2009 Feb 3.

PMID:
19195492
27.

Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection.

Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, Velan B.

PLoS Pathog. 2008 Nov;4(11):e1000211. doi: 10.1371/journal.ppat.1000211. Epub 2008 Nov 21.

28.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

PMID:
19012492
29.

Characterization of Bacillus anthracis iron-regulated surface determinant (Isd) proteins containing NEAT domains.

Gat O, Zaide G, Inbar I, Grosfeld H, Chitlaru T, Levy H, Shafferman A.

Mol Microbiol. 2008 Nov;70(4):983-99. doi: 10.1111/j.1365-2958.2008.06460.x. Epub 2008 Sep 30.

30.

Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.

Barak D, Ordentlich A, Stein D, Yu QS, Greig NH, Shafferman A.

Biochem J. 2009 Jan 1;417(1):213-22. doi: 10.1042/BJ20081276.

31.

Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase.

Mazor O, Cohen O, Kronman C, Raveh L, Stein D, Ordentlich A, Shafferman A.

Mol Pharmacol. 2008 Sep;74(3):755-63. doi: 10.1124/mol.108.047449. Epub 2008 Jun 3.

PMID:
18523134
32.

Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses.

Zvi A, Ariel N, Fulkerson J, Sadoff JC, Shafferman A.

BMC Med Genomics. 2008 May 28;1:18. doi: 10.1186/1755-8794-1-18.

33.

Flexibility versus "rigidity" of the functional architecture of AChE active center.

Shafferman A, Barak D, Stein D, Kronman C, Velan B, Greig NH, Ordentlich A.

Chem Biol Interact. 2008 Sep 25;175(1-3):166-72. doi: 10.1016/j.cbi.2008.03.013. Epub 2008 Apr 8.

34.

Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.

Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, Shafferman A, Flashner Y, Mamroud E.

Vaccine. 2008 Mar 20;26(13):1616-25. doi: 10.1016/j.vaccine.2008.01.033. Epub 2008 Feb 6.

PMID:
18304706
35.

Disparity between Yersinia pestis and Yersinia enterocolitica O:8 in YopJ/YopP-dependent functions.

Zauberman A, Velan B, Mamroud E, Flashner Y, Shafferman A, Cohen S.

Adv Exp Med Biol. 2007;603:312-20.

PMID:
17966427
36.

Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants.

Cohen O, Kronman C, Lazar A, Velan B, Shafferman A.

J Biol Chem. 2007 Dec 7;282(49):35491-501. Epub 2007 Oct 11.

38.

Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.

Chitlaru T, Gat O, Grosfeld H, Inbar I, Gozlan Y, Shafferman A.

Infect Immun. 2007 Jun;75(6):2841-52. Epub 2007 Mar 12.

39.

Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication.

Kronman C, Cohen O, Raveh L, Mazor O, Ordentlich A, Shafferman A.

Toxicology. 2007 Apr 20;233(1-3):40-6. Epub 2006 Sep 1.

PMID:
17045722
40.

Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration.

Velan B, Bar-Haim E, Zauberman A, Mamroud E, Shafferman A, Cohen S.

Infect Immun. 2006 Nov;74(11):6365-76. Epub 2006 Aug 21.

41.

Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds.

Cohen O, Kronman C, Raveh L, Mazor O, Ordentlich A, Shafferman A.

Mol Pharmacol. 2006 Sep;70(3):1121-31. Epub 2006 Jun 26.

PMID:
16801396
42.

Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Gat O, Grosfeld H, Ariel N, Inbar I, Zaide G, Broder Y, Zvi A, Chitlaru T, Altboum Z, Stein D, Cohen S, Shafferman A.

Infect Immun. 2006 Jul;74(7):3987-4001.

43.

Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis.

Zauberman A, Cohen S, Mamroud E, Flashner Y, Tidhar A, Ber R, Elhanany E, Shafferman A, Velan B.

Infect Immun. 2006 Jun;74(6):3239-50.

45.

Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

Luo W, Yu QS, Kulkarni SS, Parrish DA, Holloway HW, Tweedie D, Shafferman A, Lahiri DK, Brossi A, Greig NH.

J Med Chem. 2006 Apr 6;49(7):2174-85.

46.

Lessons from functional analysis of AChE covalent and noncovalent inhibitors for design of AD therapeutic agents.

Barak D, Ordentlich A, Kaplan D, Kronman C, Velan B, Shafferman A.

Chem Biol Interact. 2005 Dec 15;157-158:219-26. Epub 2005 Nov 11.

PMID:
16289124
47.

Host-regulated disposition of mammalian AChEs.

Kronman C, Cohen O, Velan B, Shafferman A.

Chem Biol Interact. 2005 Dec 15;157-158:51-5. Epub 2005 Nov 9.

PMID:
16289063
48.

The role of AChE active site gorge in determining stereoselectivity of charged and noncharged VX enantiomers.

Ordentlich A, Barak D, Sod-Moriah G, Kaplan D, Mizrahi D, Segall Y, Kronman C, Karton Y, Lazar A, Marcus D, Velan B, Shafferman A.

Chem Biol Interact. 2005 Dec 15;157-158:191-8. Epub 2005 Nov 10.

PMID:
16289014
49.

Functional requirements for the optimal catalytic configuration of the AChE active center.

Shafferman A, Barak D, Kaplan D, Ordentlich A, Kronman C, Velan B.

Chem Biol Interact. 2005 Dec 15;157-158:123-31. Epub 2005 Oct 27.

PMID:
16256968
50.

The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant.

Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, Levy H, Weiss S, Grosfeld H, Cohen S, Shafferman A.

Mol Microbiol. 2005 Oct;58(2):533-51.

Supplemental Content

Loading ...
Support Center